stoxline Quote Chart Rank Option Currency Glossary
  
Trevena, Inc. (TRVN)
1.22  0.01 (0.83%)    05-12 13:27
Open: 1.21
High: 1.22
Volume: 1,280
  
Pre. Close: 1.21
Low: 1.15
Market Cap: 1(M)
Technical analysis
2025-05-12 4:52:39 PM
Short term     
Mid term     
Targets 6-month :  1.61 1-year :  1.88
Resists First :  1.37 Second :  1.61
Pivot price 1.22
Supports First :  1.11 Second :  0.94
MAs MA(5) :  1.18 MA(20) :  1.2
MA(100) :  1.5 MA(250) :  3.5
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  70.1 D(3) :  62
RSI RSI(14): 48.4
52-week High :  11 Low :  0.94
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TRVN ] has closed above bottom band by 48.5%. Bollinger Bands are 35.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.22 - 1.23 1.23 - 1.23
Low: 1.14 - 1.14 1.14 - 1.15
Close: 1.21 - 1.22 1.22 - 1.23
Company Description

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Headline News

Thu, 08 May 2025
Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire

Tue, 06 May 2025
Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World

Wed, 15 Jan 2025
Trevena discontinues OLINVYK injection sales - Investing.com

Tue, 14 Jan 2025
Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World

Fri, 04 Oct 2024
Trevena Announces Receipt of Nasdaq Delisting Notification - Yahoo Finance

Thu, 20 Jun 2024
Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
OTC
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 1 (M)
Held by Insiders 812800 (%)
Held by Institutions 0.4 (%)
Shares Short 16 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.175e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 970.6 %
Return on Equity (ttm) -62.4 %
Qtrly Rev. Growth 546000 %
Gross Profit (p.s.) 66.51
Sales Per Share 0
EBITDA (p.s.) -1.2093e+006
Qtrly Earnings Growth -48.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -27 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.04
Stock Dividends
Dividend 0
Forward Dividend 59360
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android